Payload Information

General Information of This Payload
Payload ID
PAY0TXOCZ
Name
TORL7/8 agonist T785
Synonyms
TORL7/8 agonist T785
   Click to Show/Hide
Target(s) Toll-like receptor 7 (TLR7); Toll-like receptor 8 (TLR8)
 Target Info 
Structure
Formula
C18H24N6
Isosmiles
CCCCc1nc2c(N)nc3ccc(N4CCNCC4)cc3c2[nH]1
InChI
InChI=1S/C18H24N6/c1-2-3-4-15-22-16-13-11-12(24-9-7-20-8-10-24)5-6-14(13)21-18(19)17(16)23-15/h5-6,11,20H,2-4,7-10H2,1H3,(H2,19,21)(H,22,23)
InChIKey
SPPYNUDMEQYSPQ-UHFFFAOYSA-N
Pharmaceutical Properties
Molecule Weight
324.432
Polar area
82.86
Complexity
24
xlogp Value
2.4455
Heavy Count
24
Rot Bonds
4
Hbond acc
5
Hbond Donor
3
Each Antibody-drug Conjugate Related to This Payload
Full Information of The Activity Data of The ADC(s) Related to This Payload
BDC-1001 [Phase 1/2]
 ADC Info 
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Patients Enrolled
Patients with advanced metastatic HER2-expressing (IHC2/3+) or amplified solid tumors. Patients had received a median of 4 prior therapies.
Administration Dosage
4 dose levels (0.15-5.00 mg/kg) every 3 weeks.
Related Clinical Trial
NCT Number NCT04278144  Phase Status Phase 1/2
Clinical Description
Phase 1/2 study of BDC-1001 as a single agent and in combination with nivolumab in patients with advanced HER2-expressing solid tumors.
References
Ref 1 Preliminary results from a phase 1/2 study of BDC-1001, a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), in patients (pts) with advanced HER2-expressing solid tumors. J Clin Oncol. 2021 39:15_suppl, 2549-2549.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.